133 related articles for article (PubMed ID: 36185208)
1. Genomic landscape of advanced prostate cancer patients with
Swami U; Zimmerman RM; Nussenzveig RH; Hernandez EJ; Jo Y; Sayegh N; Wesolowski S; Kiedrowski LA; Barata PC; Lemmon GH; Bilen MA; Heath EI; Nandagopal L; Babiker HM; Pal SK; Lilly M; Maughan BL; Haaland B; Yandell M; Sartor O; Agarwal N
Front Oncol; 2022; 12():966534. PubMed ID: 36185208
[No Abstract] [Full Text] [Related]
2. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
3. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
4. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Khiabanian H; Frampton GM; Ross JS; Gregg JP; Lara PN; Oesterreich S; Agarwal N; Necchi A; Miller VA; Alexander B; Ali SM; Ganesan S; Chung JH
JCO Precis Oncol; 2020; 4():442-465. PubMed ID: 32903788
[TBL] [Abstract][Full Text] [Related]
5. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
[TBL] [Abstract][Full Text] [Related]
6. Roles of the PARP Inhibitor in
Inoue T; Sekito S; Kageyama T; Sugino Y; Sasaki T
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174127
[TBL] [Abstract][Full Text] [Related]
7. Detection of
McFarland TR; Mathew Thomas V; Nussenzveig R; Gebrael G; Sayegh N; Tripathi N; Sahu KK; Goel D; Maughan BL; Sirohi D; Agarwal N; Swami U
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551924
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitor Insensitivity to
Sokol ES; Jin DX; Fine A; Trabucco SE; Maund S; Frampton G; Molinero L; Antonarakis ES
JCO Precis Oncol; 2022 Jun; 6():e2100531. PubMed ID: 35772050
[TBL] [Abstract][Full Text] [Related]
9. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
10. Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with
Zhu X; Tian T; Ruan M; Rao J; Yang W; Cai X; Sun M; Qin G; Zhao Z; Wu J; Shao Z; Shui R; Hu Z
J Breast Cancer; 2018 Sep; 21(3):297-305. PubMed ID: 30275858
[TBL] [Abstract][Full Text] [Related]
11. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race.
Zimmerman R; Bilen MA; Heath EI; Nandagopal L; Swami U; Kessel A; Jaeger E; Wesolowski S; Hernanadez EJ; Chipman J; Mack A; Ravindranathan D; Maughan BL; Nussenzveig R; Yandell M; Kohli M; Lilly MB; Sartor AO; Agarwal N; Barata PC
Oncologist; 2022 Oct; 27(10):e815-e818. PubMed ID: 36036607
[TBL] [Abstract][Full Text] [Related]
13. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract][Full Text] [Related]
14. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R; Lisyanskaya A; Fedenko A; Dvorkin M; de Melo AC; Shparyk Y; Rakhmatullina I; Bondarenko I; Colombo N; Svintsitskiy V; Biela L; Nechaeva M; Lorusso D; Scambia G; Cibula D; Póka R; Oaknin A; Safra T; Mackowiak-Matejczyk B; Ma L; Thomas D; Lin KK; McLachlan K; Goble S; Oza AM
Lancet Oncol; 2022 Apr; 23(4):465-478. PubMed ID: 35298906
[TBL] [Abstract][Full Text] [Related]
15.
Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors in advanced prostate cancer: when to use them?
Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
[TBL] [Abstract][Full Text] [Related]
18. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
19. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
[TBL] [Abstract][Full Text] [Related]
20. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
